
Sign up to save your podcasts
Or
In this second phase 3 trial, the primary endpoint, BICLA, was achieved, and anifrolumab was superior to placebo for multiple secondary efficacy endpoints, including SRI(4), skin disease, and oral corticosteroid tapering.
4.3
33 ratings
In this second phase 3 trial, the primary endpoint, BICLA, was achieved, and anifrolumab was superior to placebo for multiple secondary efficacy endpoints, including SRI(4), skin disease, and oral corticosteroid tapering.
38 Listeners
52 Listeners
5 Listeners
8 Listeners
5 Listeners
3 Listeners
2 Listeners
4 Listeners
9 Listeners
38 Listeners
14 Listeners
1 Listeners
52 Listeners
0 Listeners
6 Listeners
14 Listeners
3 Listeners
26 Listeners
24 Listeners
0 Listeners